title: A naturalistic prospective open study of the effects of adjunctive therapy of sexual dysfunction in chronic PTSD patients.
abstract: BACKGROUND
  Post-traumatic Stress Disorder (PTSD) symptoms cause dysfunction in broad areas of patients' lives and those of their families. Sexual dysfunction (SD) is common in these patients and aggravates their distress, affecting overall sexual activity, desire, arousal, orgasm, activity and satisfaction. PTSD clinic patients are frequently referred for consultation and treatment in the SD clinic. This prospective naturalistic follow-up study of a random group of patients was intended to evaluate response to pharmacologic and psychotherapeutic interventions for SD, in terms of both sexual functioning and overall symptomatology.
  
  
  METHODS
  Ten patients fulfilling DSM-IV diagnostic criteria for PTSD (one woman and nine men) were recruited. Treatment for the sexual symptoms was tailored individually and was administered in addition to the continuing (stable) treatment in the PTSD clinic.
  
  
  RESULTS
  After two months of treatment for the sexual symptoms, statistically significant improvements in all domains of sexual functioning were observed. In parallel, statistically significant improvements in all domains of the Impact of Events Scale scores were observed, both on the avoidance and intrusive subscales. There were no significant differences in response to treatment in terms of time elapsed since the onset of PTSD, or the pattern or severity of sexual and PTSD symptoms.
  
  
  CONCLUSIONS
  The results of this modest study demonstrate the importance of relating to the SD of PTSD patients irrespective of the duration or severity of their disorder. In this mixed group of PTSD patients with varied duration of symptoms, both SD and PTSD core symptoms improved significantly in response to individually tailored adjunctive treatment of the SD.
authors.affiliation: Ministry of Health, Mental Health Center, Faculty of Health Sciences, Anxiety and Stress Research Unit, Ben-Gurion University of the Negev, Beersheba, Israel.
authors.forename: Bela
authors.initials: B
authors.lastname: Chudakov
authors.forename: Hagit
authors.initials: H
authors.lastname: Cohen
authors.forename: Michael Alex
authors.initials: MA
authors.lastname: Matar
authors.forename: Zeev
authors.initials: Z
authors.lastname: Kaplan
mesh_terms: D000328:Adult; D002908:Chronic Disease; D003131:Combined Modality Therapy; D000529:Complementary Therapies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011613:Psychotherapy; D011687:Purines / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000453:epidemiology*; D000068677:Sildenafil Citrate; D013313:Stress Disorders, Post-Traumatic / Q000453:epidemiology*; D013450:Sulfones / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate